Disease · MONDO_0006626
diabetic neuropathy
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. diabetic neuropathy. Diseases, record MONDO_0006626. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006626
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Amyotrophies, Diabetic, Amyotrophy, Diabetic, Asymmetric Polyneuropathy, Diabetic, Diabetic Amyotrophies, Diabetic Amyotrophy, Diabetic Asymmetric Polyneuropathies, Diabetic Asymmetric Polyneuropathy, Diabetic Autonomic Neuropathies, Diabetic Autonomic Neuropathy, Diabetic Mononeuropathies, Diabetic Mononeuropathy, Diabetic Mononeuropathy Simplex, Diabetic Mononeuropathy Simplices, Painful Diabetic Neuropathies, Painful Diabetic Neuropathy, diabetic neuropathies
- Open Targets
Drugs68
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DULOXETINE | CHEMBL1175 | Small molecule | Approval | EMA Human Drugs | 10 | 4 | 4 | Drugs and targets |
| PERAMPANEL | CHEMBL1214124 | Small molecule | Approval | TTD | 3 | 2 | 2 | Drugs and targets |
| EPALRESTAT | CHEMBL56337 | Small molecule | Approval | TTD | 2 | 1 | 1 | Drugs and targets |
| PREGABALIN | CHEMBL1059 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| LACOSAMIDE | CHEMBL58323 | Small molecule | Phase 3 | ClinicalTrials.gov and TTD | 10 | 8 | 8 | Drugs and targets |
| CAPSAICIN | CHEMBL294199 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| LIPOIC ACID, ALPHA | CHEMBL33864 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 2 | Drugs and targets |
| TRAMADOL | CHEMBL1237044 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CLONIDINE | CHEMBL134 | Small molecule | Phase 3 | TTD | 2 | 1 | 1 | Drugs and targets |
| DONAPERMINOGENE SELTOPLASMID | CHEMBL3990043 | Gene | Phase 3 | TTD | 2 | 1 | 1 | Drugs and targets |
1 to 10 of 68
See all 68 drugsTargets88
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GRIN2A | Glutamate [NMDA] receptor | 5 | Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator; Glutamate [NMDA] receptor subunit epsilon 1 antagonist | Phase 2 | https://conductscience.org/library/genes/2903 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6326 | Drugs and targets |
| SCN3A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6328 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SCN5A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6331 | Drugs and targets |
| SCN7A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6332 | Drugs and targets |
| SCN8A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6334 | Drugs and targets |
1 to 10 of 88
See all 88 targetsTrials70
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00980746 | Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy | Phase 2 | 557 | 2013-05-22 | Painful Diabetic Neuropathy | ESLICARBAZEPINE ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT00350103 | A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy | Phase 3 | 551 | 2024-03-22 | Painful Diabetic Neuropathy | LACOSAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01041859 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy | Phase 3 | 460 | 2012-05-14 | Diabetic Peripheral Neuropathy | TAPENTADOL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01496365 | Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy | Phase 2 | 452 | 2021-01-05 | Diabetic Peripheral Neuropathy | MIROGABALIN BESYLATE, PREGABALIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00235443 | A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy | Phase 2/3 | 451 | 2009-10-05 | Diabetic Neuropathy | LACOSAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01504412 | Asian Phase 2 Study for Treatment of Pain Associated With Diabetic Peripheral Neuropathy | Phase 2 | 450 | 2020-03-18 | Pain, Diabetic Peripheral Neuropathy | MIROGABALIN, PREGABALIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00220337 | A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy | Phase 3 | 371 | 2023-07-24 | Painful Diabetic Neuropathy | LACOSAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01533428 | A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN) | Phase 3 | 369 | 2015-03-13 | Diabetic Peripheral Neuropathy, Pain | CAPSAICIN | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00505284 | An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy | Phase 2/3 | 352 | 2013-02-08 | Diabetic Neuropathy | PERAMPANEL | Its record names the disease | ClinicalTrials.gov |
| NCT03219320 | Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy | Phase 2 | 301 | 2020-06-09 | Diabetic Peripheral Neuropathy | NYX-2925 | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 70
See all 70 trialsComparisons in its trials10
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Lacosamide Pooled FT and ST vs Placebo: deaths from any cause | 0 of 370 | 0 of 179 | 549 | NCT00350103 | Trial comparisons |
| Lacosamide Pooled FT and ST vs Placebo: serious adverse events | 28 of 370 | 14 of 179 | 549 | NCT00350103 | Trial comparisons |
| Pregabalin vs Placebo: serious adverse events | 9 of 198 | 2 of 186 | 384 | NCT01474772 | Trial comparisons |
| Capsaicin 8% vs Placebo: serious adverse events | 2 of 186 | 7 of 183 | 369 | NCT01533428 | Trial comparisons |
| Clonidine Gel 0.1% vs Placebo: deaths from any cause | 0 of 130 | 0 of 130 | 260 | NCT02068027 | Trial comparisons |
| Clonidine Gel 0.1% vs Placebo: serious adverse events | 12 of 130 | 7 of 130 | 260 | NCT02068027 | Trial comparisons |
| Clonidine Topical Gel (ARC-4558) vs Placebo Gel: serious adverse events | 3 of 90 | 3 of 90 | 180 | NCT00695565 | Trial comparisons |
| Clonidine Hydrochloride Topical Gel, 0.1% vs Clonidine Hydrochloride Gel Comparator: deaths from any cause | 0 of 69 | 0 of 69 | 138 | NCT02643251 | Trial comparisons |
| Clonidine Hydrochloride Topical Gel, 0.1% vs Clonidine Hydrochloride Gel Comparator: serious adverse events | 2 of 69 | 6 of 69 | 138 | NCT02643251 | Trial comparisons |
| Pregabalin vs Placebo: serious adverse events | 0 of 51 | 1 of 53 | 104 | NCT00570310 | Trial comparisons |
Papers from its trials32
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006626
GET https://conductscience.org/api/diseases/v1/MONDO_0006626/drugs?page=2